DIVIS LABORATORIES
Quarterly Results Analysis [Dec2023]
DIVIS LABORATORIES Quarterly Results
Consolidated | Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 UnAudited |
Mar2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹1,855 Cr | ₹1,909 Cr | ₹1,778 Cr | ₹1,951 Cr | ₹1,708 Cr | ₹1,855 Cr | ₹2,255 Cr | ₹2,518 Cr |
Expenses | ₹1,366 Cr | ₹1,430 Cr | ₹1,274 Cr | ₹1,463 Cr | ₹1,299 Cr | ₹1,234 Cr | ₹1,407 Cr | ₹1,414 Cr |
Operating Income | ₹489 Cr | ₹479 Cr | ₹504 Cr | ₹488 Cr | ₹409 Cr | ₹621 Cr | ₹848 Cr | ₹1,104 Cr |
Other Income | ₹95 Cr | ₹86 Cr | ₹81 Cr | ₹66 Cr | ₹113 Cr | ₹80 Cr | ₹88 Cr | ₹52 Cr |
Interest | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Depreciation | ₹95 Cr | ₹95 Cr | ₹93 Cr | ₹87 Cr | ₹87 Cr | ₹86 Cr | ₹84 Cr | ₹81 Cr |
Profit Before Tax | ₹489 Cr | ₹469 Cr | ₹492 Cr | ₹466 Cr | ₹435 Cr | ₹615 Cr | ₹852 Cr | ₹1,076 Cr |
Profit After Tax | ₹358 Cr | ₹348 Cr | ₹356 Cr | ₹321 Cr | ₹306 Cr | ₹493 Cr | ₹702 Cr | ₹895 Cr |
EPS | ₹13.51 | ₹13.13 | ₹13.43 | ₹12.09 | ₹11.55 | ₹18.60 | ₹26.45 | ₹33.70 |
Industry Peers & Returns | 1W | 1M | 1Y |
DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
CIPLA | 4.1% | -4.8% | 55.6% |
DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
MANKIND PHARMA | 1.3% | 7% | NA |
TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
LUPIN | 0.6% | 0.5% | 127.2% |
AUROBINDO PHARMA | 5.1% | 10.9% | 87.1% |
DIVIS LABORATORIES Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -2.83 % |
Y-o-Y | 8.61 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹1,855 Cr | -2.83 | |
Sep2023 | ₹1,909 Cr | 7.37 | |
Jun2023 | ₹1,778 Cr | -8.86 | |
Mar2023 | ₹1,951 Cr | 14.21 | |
Dec2022 | ₹1,708 Cr | -7.92 | |
Sep2022 | ₹1,855 Cr | -17.74 | |
Jun2022 | ₹2,255 Cr | -10.46 | |
Mar2022 | ₹2,518 Cr | - |
DIVIS LABORATORIES Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 2.09 % |
Y-o-Y | 19.56 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹489 Cr | 2.09 | |
Sep2023 | ₹479 Cr | -4.96 | |
Jun2023 | ₹504 Cr | 3.37 | |
Mar2023 | ₹488 Cr | 19.22 | |
Dec2022 | ₹409 Cr | -34.14 | |
Sep2022 | ₹621 Cr | -26.77 | |
Jun2022 | ₹848 Cr | -23.22 | |
Mar2022 | ₹1,104 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 5.06 % |
Y-o-Y | 10.06 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 26.36% | 5.06 | |
Sep2023 | 25.09% | -11.50 | |
Jun2023 | 28.35% | 13.45 | |
Mar2023 | 24.99% | 4.34 | |
Dec2022 | 23.95% | -28.46 | |
Sep2022 | 33.48% | -10.98 | |
Jun2022 | 37.61% | -14.23 | |
Mar2022 | 43.85% | - |
DIVIS LABORATORIES Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 2.87 % |
Y-o-Y | 16.99 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹358 Cr | 2.87 | |
Sep2023 | ₹348 Cr | -2.25 | |
Jun2023 | ₹356 Cr | 10.91 | |
Mar2023 | ₹321 Cr | 4.89 | |
Dec2022 | ₹306 Cr | -37.93 | |
Sep2022 | ₹493 Cr | -29.77 | |
Jun2022 | ₹702 Cr | -21.53 | |
Mar2022 | ₹895 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 5.87 % |
Y-o-Y | 7.70 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 19.3 % | 5.87 | |
Sep2023 | 18.23 % | -8.94 | |
Jun2023 | 20.02 % | 21.70 | |
Mar2023 | 16.45 % | -8.20 | |
Dec2022 | 17.92 % | -32.58 | |
Sep2022 | 26.58 % | -14.62 | |
Jun2022 | 31.13 % | -12.36 | |
Mar2022 | 35.52 % | - |
DIVIS LABORATORIES Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 2.89 % |
Y-o-Y | 16.97 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹13.51 | 2.89 | |
Sep2023 | ₹13.13 | -2.23 | |
Jun2023 | ₹13.43 | 11.08 | |
Mar2023 | ₹12.09 | 4.68 | |
Dec2022 | ₹11.55 | -37.90 | |
Sep2022 | ₹18.6 | -29.68 | |
Jun2022 | ₹26.45 | -21.51 | |
Mar2022 | ₹33.7 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD